TORONTO, Dec. 1, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS"
or the "Company") (TSX: HLS), a pharmaceutical company focused on
central nervous system and cardiovascular markets, announces that
Gilbert Godin, Chief Executive
Officer, and Tim Hendrickson, Chief
Financial Officer, will present at Stifel GMP's 2nd
Annual Future of Healthcare Conference on Wednesday December 8, 2021 at 10:30 a.m. Eastern Standard Time. The conference
will be held in a virtual meeting format.
An audio webcast of the Company's presentation will be available
at:
https://wsw.com/webcast/stifel62/register.aspx?conf=stifel62&page=hls.to&url=https://wsw.com/webcast/stifel62/hls.to/2364360
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a pharmaceutical company focused on the
acquisition and commercialization of late-stage development,
commercial stage promoted and established branded pharmaceutical
products in the North American markets. HLS's focus is on products
targeting the central nervous system and cardiovascular therapeutic
areas. HLS's management team is composed of seasoned pharmaceutical
executives with a strong track record of success in these
therapeutic areas and at managing products in each of these
lifecycle stages. For more information, please visit:
www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.